COVID-19 and immune-engaging cancer treatment
What The Viewpoint Says: This Viewpoint discusses the challenges that arise for patients with cancer who are undergoing immune-engaging therapeutic treatment during the coronavirus disease 2019 (COVID-19) pandemic.
Authors: Muhammad Bilal Abid, M.D., M.R.C.P., of the Medical College of Wisconsin in Milwaukee, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
Media advisory: The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https:/
JAMA Network Media Relations